DENVER, CO,
Jan. 08, 2019 -- InvestorsHub NewsWire -- Phoenix Life
Sciences International Limited (PLSI) (“Phoenix Life”, or the
“Company”), an international adaptive healthcare solutions company,
today announced its 2019 strategy for continued international
expansion to its shareholders.
To read the letter, see below:
Greetings
-
Today, I am happy to share with you
the Phoenix Life strategy for expansion in 2019. Last year was
record-breaking for us in many ways and we couldn’t be more excited
to enter the new year and continue to complete these important
milestones ahead of us.
The first step the company is making
to further its mission is the establishment of offices and
infrastructure in the Oceania region including Australia and the
Republic of Vanuatu. Further, this will include the
recruitment of an expanded team of medical, clinical trial,
agricultural and pharmaceutical personnel. I will be personally
relocating to the region to spearhead the growth of Phoenix Life,
and to be closer to our operations and clinical trial plans in The
Republic of Vanuatu and throughout Oceania.
We believe that the many initiatives
there will be expedited by expanding our offices and personnel in
the region. It’s important for us to build on the key relationships
that we’ve been establishing with the people and government
officials within the Pacific and further cementing Phoenix Life’s
regional and global presence to assure successful long-term
partnerships.
Secondly, as announced at the end of
last year, the approval for the importation of Phoenix Metabolic,
our diabetes management product, has paved the way for the
commencement of clinical trials in Vanuatu for the treatment and
management of Type 2 diabetes. By expanding our presence in the
region, we intend to expand access to these life and limb saving
programs into region. According to the World Health Organization,
the South Pacific contains more diabetics as a percentage of the
population that any other area in the world, with limited or no
access to treatment.
Following the anticipated success of
these international trials, Phoenix Life intends to be able to
assemble all relevant study data to support new drug applications
in developed nations such as the United States, Australia and areas
of Europe starting in 2020.
In building out our Global Production
Capacity, we’re very excited to confirm that we are in the final
stages of completing documentation and policies to acquire land to
commence propagation of regional plantations for cultivating,
extraction and processing of range of cannabis varieties to provide
the key active ingredients for Phoenix Life’s full product
portfolio. We are looking forward to not only begin local growing
and manufacturing but most importantly giving back to our partner
countries by providing local employment, education, additional
revenue streams, and most importantly positive health
outcomes.
Oceania and the South Pacific is very
important to the cannabis industry and to us because, according
to New Frontier Data, the existing cannabis
market across the region is worth an estimated $5.0 billion (U.S.
dollars). The cannabis market in Australia alone is estimated to be
worth up to $4.5 billion (U.S. dollars) as its medical cannabis
market has taken the shape of a pharmaceutical market. This is in
addition to Phoenix Life’s diabetes program. The tropical climate
of this region and its close proximity to the equator makes it
ideal for organic cannabis production because of the area’s
abundance of natural sunlight and fresh spring water. These outdoor
growing conditions significantly reduce the cost of infrastructure
and operations, while making a year-round cultivation possible.
Lastly, as we launch our global sales
organization, we are excited to bring some of the brightest minds
in sales together with healthcare professionals to open up a series
of country programs for clinical trials and product distribution.
By including both generic medical cannabis products for doctor’s
prescription as well as products designed to target and treat
specific diseases like diabetes, cancer and pain, Phoenix Life has
been positioned to start making a dramatic difference to the
healthcare of patients in the Oceania region and globally.
Building from the success of 2018,
2019 stands to be a watershed year for Phoenix Life. We look
forward to sharing many more announcements this year so please stay
tuned as our company continues to thrive and grow!
We look forward to you joining us
this year as we help shape the future of healthcare.
In service of Global Healthcare,
Martin
Tindall
Chief Executive Officer
Phoenix Life Sciences International
Limited
https://www.globenewswire.com/Tracker?data=QJ2qZfA2OjfHPYIL3RojW-tQWFfPS9_CeHdD9q5pWa8ABfQiO8JHqA7RmxBHOD2m9KvRFwEca8vvZ1WTGWwAqhlkaVgNrqHUHZcFFKT1NE8=";
rel="nofollow noopener" target="_blank">http://www.phoenixlife.co/</a> <br> <br>About
Phoenix Life Sciences International Limited<br><a
href="https://www.globenewswire.com/Tracker?data=YQ3HKTYJZiMlr21PpPIWcjrW6OTzfz6DP4JT5jsuEf2BiF0-NUHQCkSJyXAtXcpxzOdh_hrEg0sFnr4FD_pllDtD6f-bInKXpuqb1q5e3MEuToOfAD35GoWZXTS9nCK5";
rel="nofollow noopener" target="_blank">Phoenix Life Sciences
International Limited</a> is an adaptive healthcare
solutions company. Our business is to advance research and
integrate programs and manufacturing of products that target and
treat diabetes, pain, cancer, and address psychological,
gastrointestinal, autoimmune, neurological and sleep disorders. We
strive to create partnerships and integrate these programs for
human health into communities worldwide as part of our Global
Health Initiative.<br> <br>FORWARD-LOOKING
STATEMENTS<br>Information contained in this press release
regarding Phoenix Life Sciences International, Limited and its
subsidiaries, (the "Companies") may constitute forward-looking
statements or statements which may be deemed or construed to be
forward-looking statements. The words "plan", "forecast",
"anticipates", "estimate", "project", "intend", "expect", "should",
"believe," and similar expressions are intended to identify
forward-looking statements. These forward-looking statements
involve, and are subject to, known and unknown risks, uncertainties
and other factors which could cause the Company's actual results,
performance (financial or operating) or achievements to differ from
the future results, performance (financial or operating) or
achievements expressed or implied by such forward-looking
statements. The risks, uncertainties and other factors are more
fully discussed in the Company's filings with the U.S. Securities
and Exchange Commission. All forward-looking statements
attributable to the Companies herein are expressly qualified in
their entirety by the above-mentioned cautionary statement. The
Companies disclaim any obligation to update forward-looking
statements contained in this press release, except as may be
required by law.<br> <br>FOOD AND DRUG
ADMINISTRATION (FDA) DISCLOSURE<br>These statements have
not been evaluated by the FDA and therefore the products sold by
Phoenix Life Sciences International Limited are not available on
U.S.<br> <br>LEGAL
DISCLOSURE <br>Phoenix Life Sciences International
Limited does not sell or distribute any products in the United
States that are in violation of the United States Controlled
Substances Act (US.CSA). The Company does not grow, sell, or
distribute cannabis-based products in the United States and is
solely involved with the legal distribution of pharmaceutical
products that contain active ingredients derived from the cannabis
plant within international
markets. <br> <br><br>"
data-reactid="32" type="text">To learn more about Phoenix Life
Sciences International, please visit http://www.phoenixlife.co/
About Phoenix Life Sciences International
Limited
Phoenix Life Sciences International
Limited is an adaptive healthcare solutions company.
Our business is to advance research and integrate programs and
manufacturing of products that target and treat diabetes, pain,
cancer, and address psychological, gastrointestinal, autoimmune,
neurological and sleep disorders. We strive to create partnerships
and integrate these programs for human health into communities
worldwide as part of our Global Health Initiative.
FORWARD-LOOKING STATEMENTS
Information contained in this press release regarding Phoenix Life
Sciences International, Limited and its subsidiaries, (the
“Companies”) may constitute forward-looking statements or
statements which may be deemed or construed to be forward-looking
statements. The words “plan”, “forecast”, “anticipates”,
“estimate”, “project”, “intend”, “expect”, “should”, “believe,” and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements involve, and are
subject to, known and unknown risks, uncertainties and other
factors which could cause the Company’s actual results, performance
(financial or operating) or achievements to differ from the future
results, performance (financial or operating) or achievements
expressed or implied by such forward-looking statements. The risks,
uncertainties and other factors are more fully discussed in the
Company’s filings with the U.S. Securities and Exchange Commission.
All forward-looking statements attributable to the Companies herein
are expressly qualified in their entirety by the above-mentioned
cautionary statement. The Companies disclaim any obligation to
update forward-looking statements contained in this press release,
except as may be required by law.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and therefore
the products sold by Phoenix Life Sciences International Limited
are not available on U.S.
LEGAL DISCLOSURE
Phoenix Life Sciences International Limited does not sell or
distribute any products in the United States that are in violation
of the United States Controlled Substances Act (US.CSA). The
Company does not grow, sell, or distribute cannabis-based products
in the United States and is solely involved with the legal
distribution of pharmaceutical products that contain active
ingredients derived from the cannabis plant within international
markets.
Investor Contact:
Phone: 1.888.717.5655 or international +1.720.699.7222
E-mail: investor.relations@phoenixlife.co
Media Contact:
Kathryn Reinhardt
CMW Media
Kathryn@cmwmedia.com
619-972-3089
Phoenix Life Sciences (CE) (USOTC:PLSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Phoenix Life Sciences (CE) (USOTC:PLSI)
Historical Stock Chart
From Apr 2023 to Apr 2024